Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | GPR183 | P32249 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27129217 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2RECQLACACB | |
| SCHEMBL24936235 | 0.83 | NR1H2 (0.43) | USP2SMN1; SMN2NR1H2RECQLEPHX2 | |
| SCHEMBL22022990 | 0.83 | NR1H2 (0.47) | USP2SMN1; SMN2NR1H2RECQLEPHX2 | |
| SCHEMBL25275634 | 0.81 | USP2 (0.47) | USP2SMN1; SMN2RECQLACACBEPHX2 | |
| SCHEMBL18588199 | 0.79 | NR1H2 (0.44) | USP2SMN1; SMN2NR1H2RECQLEPHX2 | |
| SCHEMBL22832999 | 0.78 | USP2 (0.41) | USP2SMN1; SMN2NR1H2RECQLPIK3R1 | |
| SCHEMBL5896107 | 0.78 | USP2 (0.41) | USP2SMN1; SMN2NR1H2RECQLACACB | |
| SCHEMBL28972177 | 0.77 | USP2 (0.45) | USP2SMN1; SMN2NR1H2RECQLEPHX2 | |
| SCHEMBL23390475 | 0.76 | SMN1; SMN2 (0.36) | USP2SMN1; SMN2NR1H2ACACB | |
| SCHEMBL4543469 | 0.76 | USP2 (0.40) | USP2SMN1; SMN2NR1H2RECQLACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | USP2 34/4885SMN1; SMN2 2414/4885NR1H2 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.